Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 1:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunoglobulin E-Mediated Allergic Disorder Clear all
Completed Phase 2 Interventional Results available

Peanut Epicutaneous Phase II Immunotherapy Clinical Trial

NCT01904604
View directory record Official record
Conditions
Peanut Hypersensitivity, Food Hypersensitivity, Hypersensitivity, Hypersensitivity, Immediate
Interventions
Placebo Viaskin® Patch, Low-dose DBV712 Viaskin® Patch, High-dose DBV712 Viaskin® Patch
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 25 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Oct 2, 2026, 1:59 AM EDT
Active, not recruiting Phase 1 Interventional

Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

NCT06369467
View directory record Official record
Conditions
Food Allergy
Interventions
linvoseltamab, dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Tampa, Florida • Atlanta, Georgia • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 2, 2026, 1:59 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy

NCT01675882
View directory record Official record
Conditions
Peanut Allergy
Interventions
Viaskin Peanut 50 mcg, Viaskin Peanut 100 mcg, Viaskin Peanut 250 mcg, Viaskin Placebo
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
6 Years to 55 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
San Diego, California • Stanford, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 2, 2026, 1:59 AM EDT
Completed Phase 2 Interventional

Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen

NCT00104377
View directory record Official record
Conditions
Type I Hypersensitivity
Interventions
Grass MATA MPL
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
11
States / cities
Overland Park, Kansas • North Dartmouth, Massachusetts • St Louis, Missouri + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2010 · Synced Oct 2, 2026, 1:59 AM EDT
Completed Phase 2 Interventional Results available

Oral Immunotherapy for Childhood Egg Allergy

NCT00461097
View directory record Official record
Conditions
Hypersensitivity, Immediate Hypersensitivity, Food Hypersensitivity
Interventions
Egg oral immunotherapy, Control Group
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 18 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 2, 2026, 1:59 AM EDT
Completed Phase 2 Interventional Results available

Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children

NCT01955109
View directory record Official record
Conditions
Peanut Allergy
Interventions
Viaskin Peanut 250 mcg
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
7 Years to 56 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
San Diego, California • Stanford, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 2, 2026, 1:59 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Allergic Disease Onset Prevention Study

NCT05003804
View directory record Official record
Conditions
Atopic Dermatitis, Type 1 Hypersensitivity
Interventions
STMC-103H, Placebo
Biological
Lead sponsor
Siolta Therapeutics, Inc.
Industry
Eligibility
0 Days to 14 Days
Enrollment
283 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
24
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 2, 2026, 1:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial

NCT00580606
View directory record Official record
Conditions
Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity, Peanut Hypersensitivity
Interventions
Glycerinated peanut allergenic extract, Placebo for peanut extract (glycerin)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 2, 2026, 1:59 AM EDT
Completed Phase 2 Interventional

Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen

NCT00113750
View directory record Official record
Conditions
Type I Hypersensitivity
Interventions
TreeMATA MPL
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
10
States / cities
Mission Viejo, California • San Jose, California • Woodstock, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2010 · Synced Oct 2, 2026, 1:59 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety/Tolerability of Ragweed MATA MPL

NCT00423787
View directory record Official record
Conditions
Type I Hypersensitivity
Interventions
Ragweed MATA MPL
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 59 Years
Enrollment
993 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
59
States / cities
Waterbury, Connecticut • Atlanta, Georgia • Conyers, Georgia + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2010 · Synced Oct 2, 2026, 1:59 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Novel Biomarkers of Non-IgE Immediate Hypersensitivity Drug Reactions

NCT07605806
View directory record Official record
Conditions
Healthy Volunteer, Hypersensitivity Reactions, Vancomycin
Interventions
Vancomycin (IV)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 2, 2026, 1:59 AM EDT
Completed Phase 1 Interventional

Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing

NCT00104390
View directory record Official record
Conditions
Type I Hypersensitivity
Interventions
Grass MATA MPL
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Oct 2, 2026, 1:59 AM EDT
Completed Phase 1 Interventional

A Study to Compare the Effects of Different Sized Particles on Cells in the Nose

NCT01257191
View directory record Official record
Conditions
Hypersensitivity, Immediate, Atopic Hypersensitivity
Interventions
Carbon Black, Diesel Exhaust Particles, Fine Concentrated Ambient Particles, Ultrafine Concentrated Ambient Particles, Saline
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 2, 2026, 1:59 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy

NCT03819881
View directory record Official record
Conditions
Atopic Immunoglobulin E-Mediated Allergic Disorder
Interventions
STMC-103H, Placebo
Biological
Lead sponsor
Siolta Therapeutics, Inc.
Industry
Eligibility
2 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Stockton, California • Tustin, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 2, 2026, 1:59 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in Children

NCT04492683
View directory record Official record
Conditions
Cow's Milk Allergy
Interventions
DBV1605
Combination Product
Lead sponsor
DBV Technologies
Industry
Eligibility
29 Days to 24 Months
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 2, 2026, 1:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy

NCT01084174
View directory record Official record
Conditions
Peanut Hypersensitivity, Food Hypersensitivity, Immediate Hypersensitivity
Interventions
Peanut powder, Peanut extract, Placebo extract, Placebo powder
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
6 Years to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 2, 2026, 1:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults

NCT00850668
View directory record Official record
Conditions
Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity, Peanut Hypersensitivity
Interventions
E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3
Biological
Lead sponsor
Allertein Therapeutics, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 2, 2026, 1:59 AM EDT
Completed Phase 2 Interventional

Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test

NCT00258635
View directory record Official record
Conditions
Type I Hypersensitivity
Interventions
RagweedMATAMPL
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Novi, Michigan • Minneapolis, Minnesota • Asheville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 2, 2026, 1:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Kenota 1 CWS Method Comparison Validation Study

NCT05702671
View directory record Official record
Conditions
Allergy, Immunoglobulin E-Mediated Allergic Disorder
Interventions
Total Immunoglobulin E, Obtained From Fingerstick Sample
Diagnostic Test
Lead sponsor
Kenota Inc.
Industry
Eligibility
Up to 80 Years
Enrollment
411 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
3
States / cities
Saint Paul, Minnesota • Chapel Hill, North Carolina • Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 2, 2026, 1:59 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety/Tolerability of Grass MATA MPL

NCT00414141
View directory record Official record
Conditions
Type I Hypersensitivity
Interventions
Grass MATA MPL, Placebo
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 59 Years
Enrollment
1,028 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
65
States / cities
Colorado Springs, Colorado • Denver, Colorado • Englewood, Colorado + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2010 · Synced Oct 2, 2026, 1:59 AM EDT
Completed Phase 1 Interventional

Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy

NCT01170286
View directory record Official record
Conditions
Peanut Allergy
Interventions
Whole peanut extract, Placebo formulation
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
6 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Willingboro, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 2, 2026, 1:59 AM EDT
Completed No phase listed Observational

Study of Patients With Strongyloides Stercoralis Infection

NCT00001245
View directory record Official record
Conditions
HIV Infection, Nematode Infection, Strongyloidiasis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 80 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1989
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2009 · Synced Oct 2, 2026, 1:59 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy

NCT02636699
View directory record Official record
Conditions
Peanut Allergy
Interventions
Viaskin Peanut 250mcg, Placebo
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
4 Years to 11 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Little Rock, Arkansas • San Diego, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 2, 2026, 1:59 AM EDT